Zomedica Corp. - $ZOM STOCK NEWS

Zomedica Corp. received CE certification for its VetGuardian(R) remote contactless monitoring system, opening doors for European expansion in the $4 billion vet services market. The system utilizes radar technology for stress-free and efficient patient monitoring, enhancing operational workflow and outcomes. This milestone allows Zomedica to tap into the growing demand from veterinarians worldwide, driving innovation in the veterinary health sector.

Zomedica Corp. strengthens its market position with the issuance of three new patents for its TRUFORMA diagnostic platform. The patents cover innovative design and functionality improvements, enhancing the system's ability to detect a wide array of health conditions in horses and companion animals. With a total of 65 U.S. patents, 123 international patents, and 33 U.S. and 98 foreign trademarks, Zomedica solidifies its intellectual property portfolio and market presence in the veterinary health industry.

Zomedica Corp will report its first quarter 2024 financial results on May 9th, 2024, providing insights into its operational and financial performance. The company, focused on veterinary health products, will host a conference call and webcast to discuss the highlights of the quarter.

Senstar Technologies announced its financial results for the fourth quarter and full year of 2023. The company will host a conference call to discuss its operational and financial highlights on April 1st, 2024.

Zomedica Corp. announced CEO Larry Heaton will present at Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference. The presentation will include a Q&A session and 1x1 meetings with the management team. The event will be webcast live and available for 90 days on the company's website and Channelchek.

Zomedica Corp. (ZOM) reported strong financial results for Q4 and full year 2023, with revenue growth of 33% to $25.2 million driven by increases in Therapeutic Devices and Diagnostics segments. The company achieved record revenue in Q4, with 19% growth to $7.3 million. Zomedica made strategic acquisitions, launched new products, and expanded manufacturing capabilities in 2023. The company's cash position was robust at $100.5 million. However, Zomedica reported a net loss of $34.5 million for 2023, with increased operating expenses and research costs. Adjusted Non-GAAP EBITDA loss was $12.8 million.

Zomedica Corp. (ZOM) will host a conference call to discuss its Q4 and Full Year 2023 financial results on April 1st, 2024. The call will cover operational and financial highlights for the period ended December 31, 2023, followed by a Q&A session.

Zomedica Corp. (ZOM) announces a peer-reviewed research study comparing its TRUFORMA diagnostic platform for feline hyperthyroidism to CLIA platforms, showing improved accuracy. The study suggests TRUFORMA's BAW technology provides more precise results, aiding in early diagnosis. Zomedica collaborates with researchers to enhance animal healthcare, focusing on in-clinic diagnostics for various conditions.

Zomedica Corp. is in dialogue with NYSE American to regain compliance with listing standards after receiving a notice in 2023. The company held a Special Meeting of Shareholders but failed to effect a share consolidation action. CEO Larry Heaton is optimistic about the future despite the risk of delisting.